Novo Nordisk and Orbis Medicines have signed a multi-target discovery and licensing agreement worth up to $1.4 billion to pursue oral medicines for cardiometabolic conditions that are often treated with injections.

The agreement includes upfront and milestone payments, tiered royalties and a strategic investment by Novo in Orbis. The headline value is therefore conditional on development and commercial progress; it is not an immediate payment or an approved-product valuation.

Why macrocycles matter

Orbis will use its AI-enabled nGen platform to discover synthetic macrocycles. These ring-shaped molecules may reach biological targets that are difficult for conventional small-molecule tablets while retaining the potential for oral delivery.

Orbis reported oral bioavailability of up to 18% in preclinical work. That is an early scientific signal, not proof of safety, effectiveness or future approval in people. Drug candidates still face discovery, toxicology, clinical trials, manufacturing and regulatory review.

Source: Reuters, 17 September 2026.

Why the GCC healthcare market should watch

The Gulf has a high burden of obesity, diabetes and related cardiovascular disease. Oral alternatives could expand the number of people willing or able to begin treatment, simplify distribution and change how clinics build follow-up programs.

The change would also challenge business models built around administering injections. Providers can protect value by focusing on diagnosis, appropriate prescribing, adherence, nutrition, monitoring and documented outcomes rather than the procedure alone.

Karim's strategic takeaway

Convenience can expand a healthcare category, but access without follow-up does not guarantee better outcomes. Gulf providers should prepare for a market where medication delivery becomes easier and the differentiated service becomes patient selection, trust, monitoring and sustained behavioral support.